GlassScriptPhysician profile
Ravi Chinthakindi
NPI 1699940379
$1,991.54
in general payments reported to CMS, 2019-2025
25 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $104 · 2021: $88.99 · 2022: $191 · 2023: $293 · 2024: $531 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.50 | 2020-2024 | Avycaz, Teflaro, Dalvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.25 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $127.07 | 2023-2025 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $126.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $125.35 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.37 | 2025 | Caplyta |
| Novo Nordisk INC | $100.53 | 2020-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $81.67 | 2025 | Watchman Flx |
| Allergan, INC. | $81.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.77 | 2024 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $74.34 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $65.24 | 2019-2024 | Veozah |
| Ucb, INC. | $47.86 | 2023-2025 | Fintepla |
| Otsuka America Pharmaceutical, INC. | $46.91 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $46.69 | 2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $46.55 | 2024 | |
| Sanofi-Aventis U.S. LLC | $37.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $34.70 | 2019 | |
| Cipher Pharmaceuticals US LLC | $31.38 | 2025 | Natroba, Spinosad |
| Merck Sharp & Dohme LLC | $31.25 | 2024 | Recarbrio, Dificid, Zerbaxa |
| Amgen INC. | $30.45 | 2025 | Evenity |
| Insmed, INC. | $23.80 | 2025 | Arikayce |
| Alkermes, INC. | $17.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.29 | 2023 | Xifaxan |
| Edwards Lifesciences Corporation | $14.14 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Chinthakindi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.